marijuanamoment.net
Bipartisan Congressional Psychedelics Caucus Lays Out Plan For Federal And State Cooperation To Increase Therapeutic Access
A new report from a bipartisan psychedelics caucus in Congress summarizes stakeholders' views on how the therapeutic use of substances like psilocybin, ibogaine and DMT can be "safely and ethically integrated" into the U.S. healthcare system, emphasizing the need for collaboration across federal agencies and with states. The document, published on Thursday by the Congressional Psychedelics Advancing Therapies (PATH) Caucus, comes after lawmakers in 2024 issued a request for information (RFI) seeking input from experts about how to best set up a regulatory framework for psychedelic medicines. An analysis of responses to the RFI found "broad consensus among clinicians, researchers, veteran advocates, Tribal leaders, payors, regulators, and patients that could offer safe, equitable, and evidence‑based treatment for a wide array of treatment-resistant conditions," a press release from the caucus says about the new report.